Signs of Primary Pulmonary Hypertension
Links shared publicly online about this topic
Pulmonary Hypertension, Primary: eMedicine Pulmonology
emedicine.medscape.com — “Overview: Primary pulmonary hypertension (PPH) is a rare disease characterized by elevated pulmonary artery pressure with no apparent cause. PPH is also termed precapillary pulmonary hypertension or, more recently, idiopathic pulmonary arterial hypertension (IPAH). The term IPAH ...” View full resource at emedicine.medscape.com
Most Recently Shared on March 26, 2010 at 8:09 pm By:
Medscape Pulmonary Health Site
Joint AHA/ACC guidelines with extensive PAH coverage; check out the newly updated article at http://bit.ly/9NNQSC
About Pulmonary Hypertension
lifespan.org — “About Pulmonary Hypertension” View full resource at lifespan.org
Most Recently Shared on November 10, 2009 at 7:09 pm By:
It's pulmonary hypertension awareness month. Do you know the signs? http://bit.ly/PulmHyp
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint - Drugs.com MedNews
drugs.com — “Conference Call to be Held at 9 00 a.m. Eastern Time on August 24, 2011 United Therapeutics Corporation (NASDAQ UTHR) announced today the completion of its FREE” View full resource at drugs.com
Most Recently Shared on August 24, 2011 at 2:10 pm By:
Drugs and Devices OW OW Health
FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint:... http://t.co/w6H23Ib #drug
Pulmonary arterial hypertension: --An early diagnosis makes a difference - JAAPA
jaapa.com — “With knowledge of what to look for and a systematic approach to the evaluation, physician assistants can make this challenging diagnosis in the primary care setting.” View full resource at jaapa.com
Most Recently Shared on May 2, 2011 at 2:57 pm By:
Pulmonary arterial hypertension: An early diagnosis makes a difference: With knowledge of what to look for and ... http://bit.ly/jXAfAi
ESC> Communities> ESC Working Groups> Myocardial and Pericardial Diseases> Education & Research> Paper of the month> A meta-analysis of randomized controlled trials in pulmonary hypertension
escardio.org — “ESC> Communities> ESC Working Groups> Myocardial and Pericardial Diseases> Education & Research> Paper of the month> A meta-analysis of randomized controlled trials in pulmonary hypertension” View full resource at escardio.org
Most Recently Shared on June 17, 2009 at 7:54 am By:
European Cardiology Cardiology and Medical Society
A meta-analysis of randomised controlled trials in pulmonary hypertension: An update on pulmonary hypertension http://tinyurl.com/m3hbun
Leukemia Drug Sprycel (Dasatinib) Has Risk Of Pulmonary Arterial Hypertension, Warns FDA - QualityPoint Technologies
qualitypointtech.net — “Sprycel (dasatinib), a leukemia medication raises the risk of developing pulmonary arterial hypertension, the US Food and Drug Administration (FDA) announced today in a Drug Safety Communication. The FDA says doctors should check patients for signs and symptoms of underlying cardiopulmonary disease before considering prescribing Sprycel - they should also evaluate patients during treatment. Pulmonary arterial hypertension, also known as pulmonary hypertension or PAH is a kind of high blood press” View full resource at qualitypointtech.net
Most Recently Shared on October 12, 2011 at 1:45 am By:
Leukemia Drug Sprycel (Dasatinib) Has Risk Of Pulmonary Arterial Hypertension, Warns FDA: Sprycel (dasatinib), a l... http://t.co/GNLdl0qX
Actelion Pharmaceuticals launches Epoprostenol for Injection for treatment of primary pulmonary hypertension
news-medical.net — “Actelion Pharmaceuticals US, Inc. today announced the commercial availability of Epoprostenol for Injection, an improved formulation of epoprostenol that is stable at room temperature, for the treatment of primary pulmonary hypertension and pulmonary hypertension associated with scleroderma spectrum of disease in NYHA Class III and Class IV patients.” View full resource at news-medical.net
Most Recently Shared on April 22, 2010 at 3:39 pm By:
HIV/AIDS News: Actelion Pharmaceuticals launches Epoprostenol for Injection for treatment of primary pulmonary hyp... http://bit.ly/8Z7vDQ
theheart.org: trusted cardiology news and opinions
theheart.org — “The latest developments in cardiology and cardiovascular research, including heartwire news and commentary by some of the world's top cardiologists. Sign up for free.” View full resource at theheart.org
Most Recently Shared on May 12, 2011 at 8:55 pm By:
Pulmonary hypertension curbs MV repair results: Preoperative pulmonary hypertension is an independent predictor ... http://bit.ly/lj1RLX
Summary Box: Pfizer Takes Thelin off the Market - ABC News
abcnews.go.com — “Summary Box: Pfizer Takes Thelin off the Market” View full resource at abcnews.go.com
Most Recently Shared on December 11, 2010 at 5:56 pm By:
The Kidney Group Physician Group and Nephrology
Pfizer Takes Thelin for pulmonary artery hypertension off the Market. http://abcnews.go.com/Business/wireStory?id=12366050
Pseudotumor Cerebri, Pediatric Perspective: eMedicine Neurology
emedicine.medscape.com — “Overview: Pseudotumor cerebri (PTC), or idiopathic intracranial hypertension, is characterized by signs and symptoms of increased intracranial pressure (ICP) in the absence of a space-occupying lesion. Pseudotumor cerebri should be divided into primary (idiopathic) and secondary forms. ...” View full resource at emedicine.medscape.com
Most Recently Shared on December 8, 2009 at 3:16 pm By:
Medscape Neurology Neurology and Health Site
Pseudotumor Cerebri, Pediatric Perspective: eMedicine Neurology http://bit.ly/4MpkqM
theheart.org: trusted cardiology news and opinions
theheart.org — “The latest developments in cardiology and cardiovascular research, including heartwire news and commentary by some of the world's top cardiologists. Sign up for free.” View full resource at theheart.org
Most Recently Shared on May 19, 2011 at 9:40 pm By:
ASA-STAT: Aspirin/statins fail in pulmonary arterial hypertension: Neither agent showed any benefit on the prima... http://bit.ly/lwkqFc
COPD (Chronic Obstructive Pulmonary Disease) Symptoms, Causes, and Treatments by MedicineNet.com
medicinenet.com — “Learn about copd (chronic obstructive pulmonary disease) symptoms such as chronic cough, shortness of breath, and frequent respiratory infections. emphysema, smoking, and chronic bronchitis symptoms may be more complicated.” View full resource at medicinenet.com
Most Recently Shared on December 19, 2009 at 8:31 am By:
MedicineNet: Chronic Obstructive Pulmonary Disease http://bit.ly/58UwN0 Full http://bit.ly/5rqBcp
United Therapeutics Drug Misses Goals - WSJ.com
online.wsj.com — “United Therapeutics Corp.'s oral-drug candidate to treat pulmonary arterial hypertension failed to meet its primary goals.” View full resource at online.wsj.com
Most Recently Shared on August 24, 2011 at 3:41 pm By:
United Therapeutics Drug Candidate Misses Goals http://t.co/8GAYank
What Is the Most Cost- Effective Evaluation for a First Syncopal Episode :: Article - The Hospitalist
the-hospitalist.org — “Case A 71-year-old woman is admitted after losing consciousness and falling at home. Her history is significant for hypertension, bilateral internal carotid artery stenoses, chronic kidney disease, and diabetes. Resting vital signs are normal. Cardiac, pulmonary, and neurologic exams are unremarkable, as is an electrocardiogram ECG. She was noted...” View full resource at the-hospitalist.org
Most Recently Shared on September 6, 2010 at 4:05 pm By:
Wiley Health Medical Health Site
What Is the Most Cost- Effective Evaluation for a First Syncopal Episode? http://ow.ly/2yL1e
Invida to continue commercialization of Actelion's Tracleer for PAH in crucial Asian markets
news-medical.net — “Invida Group, the leading provider of healthcare brands and services to the Asia Pacific region, today announced that its contract with Swiss biotechnology company, Actelion, has been extended through 2015 to continue commercialization of Tracleer® for the treatment of pulmonary arterial hypertension (PAH) in crucial markets throughout Asia. Actelion signed with Invida initially in 2005, and has extended the contract to market the company's lead product, Tracleer, in Thailand, Malaysia,” View full resource at news-medical.net
Most Recently Shared on March 26, 2010 at 5:40 pm By:
HIV/AIDS News: Invida to continue commercialization of Actelion's Tracleer for PAH in crucial Asian markets: Invid... http://bit.ly/9Xv8bn
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Medscape Pulmonary
Latest medical news, articles, and features from Medscape Pulmonary Medicine.
-
RI Hospital/Nancy
Advancing medicine. Touching lives. We are the largest teaching hospital and major trauma center in RI focused on high quality care, safety and research.
-
Drugs and Devices OW
Organizing drug and medical device resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
